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VDACsAltered dopamine homeostasis plays a key role in the pathogenesis of Parkinson's disease. The generation of
reactive oxygen species by spontaneous dopamine oxidation impairs mitochondrial function, causing in turn
an enhancement of oxidative stress. Recent ﬁndings have highlighted the role of mitochondrial outer membrane
proteins in the regulation of the correct disposal of damaged mitochondria. Here, we report the effect of altered
dopamine homeostasis on the mitochondrial functionality in human neuroblastoma SH-SY5Y cells, a cellular
model widely used to reproduce impaired dopamine homeostasis. We observed that dopamine signiﬁcantly
and relevantly reduces VDAC1 and VDAC2 levelswithout any change in themRNA levels. Althoughmitochondria
are depolarized by dopamine and mitochondrial calcium inﬂux is reduced, dysfunctional mitochondria are not
removed by mitophagy as it would be expected. Thus, alteration of dopamine homeostasis induces a mitochon-
drial depolarization not counteracted by the mitophagy quality control. As a consequence, the elimination of
VDACs may contribute to the altered mitochondrial disposal in PD pathogenesis, thus enhancing the role of
oxidative stress.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Voltage-dependent anion channels (VDACs, also known as mito-
chondrial porins) are the most abundant proteins of the outer mito-
chondrial membrane. In mammals, the VDAC family consists of three
proteins VDAC1, VDAC2 and VDAC3 [1]. They mediate the ﬂow of ions
andmetabolites between the cytoplasm and themitochondrial network
and regulate Ca2+ signaling [2,3]. The recent studies about their role in
regulating apoptosis, autophagy and energy production pointed out
that they are much more than simple channels that passively allow
the transit from and to mitochondria and that their activity is isoform-
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o).Altered dopaminehomeostasis and oxidative stress play a key role in
the pathogenesis of Parkinson's disease (PD) [5–7]. Free cytosolic dopa-
mine spontaneously oxidizes and generates reactive oxygen species
(ROS) that impairmitochondrial functionality [8]. VDAC levels were ob-
served to decrease in human neuroblastoma NMB cells after dopamine
treatment, and this down-regulation was linked to dopamine-induced
apoptosis [9]. Recently, the complete disappearance of one spot corre-
sponding to VDAC2was reported in the two-dimensional electrophore-
sis (2-DE) pattern of dopamine-treated human neuroblastoma SH-SY5Y
cells [10]. Besides a strong evidence for a role of VDACs in regulating the
apoptotic process, the biochemical mechanisms involved are not well
characterized [4]. Ca2+ ﬂux tomitochondria is considered an important
signal for apoptosis induction [11]. In this view, the role of VDAC1 in the
transmission of the low-amplitude apoptotic Ca2+ signal to mitochon-
dria may justify its apoptotic feature [12].
A role of VDACs has been recently proposed also in guiding the
mitophagic process [13]. It is still a matter of debate whether the three
VDACs have an isoform-dependent role and whether they are dispens-
able in directing altered mitochondria to the autophagosome [13–15].
According to several reports, impaired mitochondria are labeled for
mitophagy by parkin, a PD-related E3 ubiquitin ligase, after activation
by PINK1, a PD-related protein kinase [14,16,17]. Strikingly, VDAC1 was
identiﬁed as a target for parkin-mediated Lys27 poly-ubiquitinylation
and mitophagy [14]. Thus, these data provide functional links between
Table 1
Sequences of speciﬁc primers: F = forward primer; R = reverse primer.
Gene Primer sequence Amplicon size (bp)
VDAC1 F 5′-GGGGCCCGGAAGGCAGAAGA-3′ 82
VDAC1 R 5′-GCCCTTGGTGAAGACATCCTTGG-3′
VDAC2 F 5′-CGGGGTCCTGTCTGGGAGAG-3′ 70
VDAC2 R 5′-GCTGGAGGGCGAAGTGAAGG -3′
GAPDH F 5′-GAGTCAACGGATTTGGTCGT-3′ 238
GAPDH R 5′-TTGATTTTGGAGGGATCTCG-3′
1817T. Alberio et al. / Biochimica et Biophysica Acta 1842 (2014) 1816–1822PINK1, parkin and the selective autophagy of mitochondria, which is
implicated in the pathogenesis of PD [14].
In this view, the effect of impaired dopamine homeostasis on VDACs
and on the relatedmitophagy pathway appears of great interest. To this
purpose,we have investigated VDAC levels and the disposal of damaged
mitochondria in human neuroblastoma SH-SY5Y cells, a cellular model
widely used to reproduce impaired dopamine homeostasis [5].
2. Material and methods
2.1. Cells
Human neuroblastoma SH-SY5Y cells were obtained from the
European Collection of Cell Cultures (Cat No. 94030304; Lot No.
11C016) and were cultured in 5% CO2 humidiﬁed atmosphere at 37 °C
in high-glucose Dulbecco's modiﬁed Eagle's medium (DMEM) with
10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml strepto-
mycin, and 2 mM L-glutamine. All cell culture media and reagents
were from Euroclone. Cells were treated for different times with
0.25 mM dopamine (Sigma-Aldrich) in the presence of 700 U/ml cata-
lase (Sigma-Aldrich) to eliminate aspeciﬁc effects due to H2O2 arising
from dopamine auto-oxidation [9].
For the time-course analysis, cells were treated or not for 3, 7 and
24 h with dopamine. To verify autophagy induction, 50 μM
chloroquine was added to cells under 24 h dopamine treatment for
the last 2 h. To induce autophagy, cells were treated overnight with
1 μM rapamycin. To inhibit proteasome, 1 μMMG132 (Sigma-Aldrich)
was added to cells already treated with dopamine for 8 h, for other 16 h.
2.2. Quantitative Western blotting analysis
Cells were collected by centrifugation (300 ×g, 5 min, 25 °C) and
resuspended in 100 μl RIPA buffer (25 mM Tris–HCl, pH 7.4, 150 mM
NaCl, 1% Triton X-100, 1% SDS, 1% sodiumdeoxycholate) in the presence
of protease (Sigma-Aldrich) and phosphatase (Roche) inhibitors
(30 min, 4 °C under shaking). Extracts were cleared by centrifugation
(10,000×g, 30min, 4 °C) and protein concentration in the supernatants
was determined spectrophotometrically with the bicinchoninic acid
assay (Pierce).
Cell lysates (40 μg) were denatured in Laemmli sample buffer for
5 min at 98 °C and electrophoresed on 13% SDS-PAGE gel. Gels were
transferred to polyvinylidene diﬂuoride (PVDF)membranes (Millipore)
at 1.0 mA/cm2, 1.5 h (TE77pwr, Hoefer). Membranes were saturated in
5% non-fat milk or 5% BSA in TBS-T (10 mM Tris–HCl pH 7.4, 150 mM
NaCl and 0.05% Tween-20) and incubated in the same buffer at 4 °C
overnight with rabbit anti-VDAC1 polyclonal antibody (Abcam), 1:600
dilution, with rabbit anti-VDAC2 polyclonal antibody (Sigma-Aldrich),
1:250 dilution, with rabbit anti-LC3 polyclonal antibody (Cell Signal-
ing), 1:1000 dilution, with mouse anti-β-actin monoclonal antibody
(GeneTex), 1:3000 dilution, or with rabbit anti-cytochrome-c-oxidase
subunit 5B (COX5B) (Sigma-Aldrich), 1:1000 dilution. Membranes
were then washed with TBS-T and incubated with peroxidase-
conjugated anti-rabbit-IgG antibody (Thermo Scientiﬁc), 1:1000 in 5%
milk-TBS-T, or anti-mouse-IgG antibody (Millipore), 1:3000 in 5%
milk-TBS-T, respectively, for chemiluminescence detection (Millipore).
Images (16 bit grayscale) were acquired with G:BOX Chemi XT4
(Syngene) system and analyzed using ImageJ software (http://rsb.info.
nih.gov/ij/). Signal intensitieswere corrected for protein loading by nor-
malization to β-actin intensity. Statistical signiﬁcance was veriﬁed by
Student's t test with Welch correction for heteroscedasticity.
2.3. RNA extraction, retrotranscription and quantitative PCR
RNA was extracted using SV total RNA isolation system (Promega)
following the manufacturer's instructions and treated with rDNase in
order to remove genomic DNA. The integrity of RNA was veriﬁedloading total RNA onto an agarose gel and visualizing the two bands of
rRNA 28S (5 kb) and 18S (2 kb). One microgram of RNA was reverse
transcribed into ﬁrst-strand cDNA in a 20 μl ﬁnal volume using the
GoTaq® 2-Step RT-qPCR System (Promega). PCR was performed by
Real-Time PCR (DNA Engine Opticon 2; MJ Research, USA) using a
SYBR Green PCR mix (Promega). The expression of VDAC1 and VDAC2
was evaluated using primers reported in Table 1 after 2, 6 and 24 h do-
pamine treatment. Results were conﬁrmed by three independent repli-
cates. The speciﬁcity of the ampliﬁed products was checked by the
melting temperature curve analysis and the expected size of the frag-
ments was further visualized in a 2% agarose gel stained with ethidium
bromide. Statistical signiﬁcance was veriﬁed by Student's t test with
Welch correction for heteroscedasticity.2.4. Measurement of Ca2+ ﬂux to mitochondria using Aequorin
Ca2+ measurements were performed by means of a luminescence
system based on aequorin, a Ca2+-sensitive globular protein containing
a hydrophobic core cavity that accommodates the prosthetic group
coelenterazine. Upon Ca2+ binding to aequorin EF-hand domains,
coelenterazine is released (as coelenteramide) and a photon is emitted.
Due to the huge dynamic range of aequorin-based probes, the technique
is highly quantitative [18]. Activation of a membrane receptor coupled
to a Gq protein leads to activation of PLCβ production of IP3 and thus
opening of ER Ca2+ releasing channel (IP3R), with a consequent in-
crease of [Ca2+] both in the cytosol and in the mitochondrial matrix.
SH-SY5Y cells express bradykinin receptors (type B2) that trigger the
release of Ca2+ from the intracellular stores and thus activation of
Ca2+ signaling [19].
In detail, 24 h before the transfection step, SH-SY5Y cellswere plated
on a 13mmround coverslip at 30–50% conﬂuence. Just before the trans-
fection procedure, cells were washed with 1 ml of fresh medium. For
each coverslip, 5 μl of 2.5MCaCl2 solutionwas added to 4 μg ofMTS (mi-
tochondrial target sequence)-aequorin (mtAEQ) DNA dissolved in 45 μl
of Tris-EDTA (10mMTrizma-base, 1 mMEDTA, pH 8). The solutionwas
mixed and added to 50 μl of HEPES Buffered Saline Solution (HBS 2×,
280 mM NaCl, 50 mM Hepes, 1.5 mM Na2HPO4, pH 7.12) while
vortexing, and incubated for 30min at RT. After 16 h, cells were washed
three times with PBS and then treated or not with 0.25 mM dopamine
for 24 h. One hour beforemeasurements, cellswere placed in KRB saline
solution (in the presence of 1 mM CaCl2 and 1.0 g/l glucose) supple-
mented with synthetic coelenterazine (5 μM) for aequorin reconstitu-
tion. The coverslip with transfected cells was transferred to the
luminometer chamber and perfused with Krebs–Ringer bicarbonate
(KRB) saline solution in the presence of 1 mM CaCl2 and 1.0 g/l glucose
to remove the excess of coelenterazine. Bradykinin (100nM)was added
to the perfusingmedium. Each experimentwas terminated by lysing the
cellswith 100 μMdigitonin in ahypotonic Ca2+-rich solution (10mMCaCl2
in H2O), thus discharging the remaining aequorin pool. The light signalwas
collectedbymeansof a low-noisephotomultiplier placed in closeproximity
(2–3mm) to aequorin expressing cells, and calibrated into [Ca2+] values by
an algorithmbased on theCa2+ response curve of aequorin at physiological
conditions of pH, [Mg2+] and ionic strength, as previously described [20].
Data are presented as representative traces and bar graphs showing the
mean of the [Ca2+] peak value reached during cellular stimulation.
Fig. 1. Relative VDAC1(panel A), VDAC2 (panel B) and COX5B (panel C) protein levels
measured by Western blotting. VDAC1 level is reduced by 50% after 24 h, whereas
VDAC2 is decreased by one half after 3 h and is progressively diminished in the following
time. COX5B levels remain constant. Bars represent average values of three independent
experiments ± SEM. Open bars: control; ﬁlled bars: dopamine treatment. *, p b 0.05; **,
p b 0.005.
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2.5. Detection of mitochondrial membrane potential (ΔΨm) loss
4 × 105 SH-SY5Y cells were seeded on a 24mm coverslip and grown
for 24 h. Afterwards, they were treated or not with 0.25 mM dopamine
in the presence of 700 U/ml catalase for 24 h. For measurement of
the mitochondrial membrane potential (ΔΨm), cells were loaded with
100 nMMitoTracker Red CMXRos (chloromethyl-X-rosamine, Molecu-
lar Probes, Invitrogen), for 20 min at 37 °C and then placed in a
thermostated chamber on the stage of a Zeiss Axiovert 200 invertedmi-
croscope equipped with a BD Carv-II confocal head and a high sensitiv-
ity back-illuminated EM-CCD camera (Cascade 512b, Photometrics).
Images were taken with a 63 × 1.4 N.A. Plan-Apochromat objective
with 500 ms exposure time. CMXRos emission was quantiﬁed by mea-
suring the average pixel intensity of the whole ﬁeld of view (fov) on
background-corrected images with the Image-J software. Each fov in-
tensity was normalized with respect to the number of cells as deﬁned
by nuclear staining with 4′,6-diamidino-2-phenylindole (DAPI). Linear-
ity between CMXRos emission normalized on DAPI staining and on cell
counting was assessed by quantile-quantile plots (Supplementary
Fig. 1). At least twelve fov were evaluated for each condition. Mean ±
SEM emission values were obtained from three independent experi-
ments. Statistical signiﬁcance was veriﬁed by Student's t test with
Welch correction for heteroscedasticity.
2.6. Immunoﬂuorescence microscopy
Cells were plated on 15-mm glass coverslips in 12-well dishes and
treated with 0.25 mM dopamine for 24 h. Cells were washed once
with PBS and ﬁxed in 4% paraformaldehyde (PFA) in PBS for 15 min,
permeabilized in 0.2% Triton X 100 in PBS for 5 min, and blocked in 5%
FBS in PBS for 1 h at room temperature (RT). Coverslips were incu-
bated with rabbit anti-COX5β (Sigma-Aldrich, 1:200) for 2 h at RT,
washed 3 × 10 min with PBS and incubated for 1 h at RT with goat
anti-rabbit 488 secondary antibody (Invitrogen, 1:1000). Cover-
slips were incubated with 300 nM DAPI (Invitrogen) in PBS for
3 min, then washed 3 × 10 min with PBS and mounted on glass
slides with Prolong® Gold antifade reagent (Invitrogen). Images
were collected on a Nikon Eclipse Ni-U upright microscope with a
CFI Plan Fluor 100 × 1.30 NA objective (Nikon).
3. Results
3.1. Time-course of VDAC1 and VDAC2 protein levels
To characterize time-dependent changes of VDAC levels, we
performed a time-course evaluation of VDAC1 and VDAC2 by Western
blotting after 3, 7 and 24 h dopamine exposure. As shown in Fig. 1A,
the VDAC1 level was signiﬁcantly diminished to one half after 24 h
treatment with 0.25 mM dopamine. This dopamine concentration gen-
erates reactive oxygen species intracellularly (Supplementary Fig. 2)
and was consequently chosen to produce an effect on mitochondrial
protein turnover. Conversely, the VDAC2 level (Fig. 1B) was already
signiﬁcantly reduced after 3 h treatment, with a further reduction at
subsequent time points. After 24 h dopamine treatment the VDAC2
signal was barely detectable.
3.2. Effect of dopamine treatment on the number of mitochondria
To verify that VDAC downregulation was not due to a general de-
crease in the number of mitochondria, we determined the level of
housekeeping mitochondrial proteins, such as grp75, HSP60 (data not
shown) and COX subunit 5B (Fig. 1C). Western blotting analysis did
not show signiﬁcant changes in their levels, neither in controls (culturetime effect) nor in SH-SY5Y dopamine-treated cells for different times
(treatment effect), thus conﬁrming a speciﬁc effect of dopamine on
VDACs abundance.
3.3. Time-course of VDAC1 and VDAC2 mRNA levels
To explore the correlation betweenVDAC1 andVDAC2 protein levels
with the related mRNA levels, we investigated VDAC1 and VDAC2 ex-
pression after dopamine treatment by RT-Real-time PCR. Our results
showed that dopamine treatment up-regulated the VDAC1 mRNA
level at early times (Fig. 2). Conversely, VDAC2 mRNA levels did not
show any signiﬁcant change during the whole time-course.
3.4. Ca2+ ﬂux to mitochondria
Taking into account the downregulation of VDACs and their role in
regulating Ca2+ signaling, we measured the ﬂow of Ca2+ to the
Fig. 2. Relative VDAC1 (panel A) and VDAC2 (panel B) mRNA levels measured by quanti-
tative PCR. VDAC1 transcription is activated by dopamine at 6 h, whereas it returns to the
control value after 24 h. Dopamine does not affect VDAC2 transcription. Bars represent
average values of three independent experiments ± SEM. Open bars: control; ﬁlled
bars: dopamine treatment. *, p b 0.05.
Fig. 3.Calcium ionﬂux intomitochondria. Panel A reports representative curves (closest to
the average value at the peak maximum) of calcium ion mitochondrial inﬂux in control
conditions (continuous line) and after 24 h dopamine treatment (dashed line). Panel B re-
ports mean± SEM values for the peakmaximumof nine independent experiments. Open
bars: control; ﬁlled bars: 24 h dopamine treatment. **, p b 0.005.
1819T. Alberio et al. / Biochimica et Biophysica Acta 1842 (2014) 1816–1822mitochondria in dopamine treated cells. Recombinant aequorin was
targeted to the mitochondria (mtAEQ) to reveal calcium ion ﬂux to mi-
tochondria and 100nMbradykininwas used as a trigger to detect a peak
in this ﬂux (see Material and methods, Section 2.4.). Fig. 3A reports a
representative measurement of Ca2+ mitochondrial inﬂux in control
conditions (continuous line) and following dopamine treatment
(dashed line). The Ca2+ ﬂux to mitochondria was signiﬁcantly reduced
by dopamine to 75% of the basal value after 24 h (Fig. 3B).3.5. Effect of dopamine on the mitochondrial membrane potential and
network
To verify whether the dopamine-induced down-regulation of
VDAC1 and VDAC2was accompanied with changes in themitochondri-
al membrane potential ΔΨm, dopamine-treated cells were collected at
24 h after treatment. Fig. 4A shows that dopamine decreased the mito-
chondrial membrane potential ΔΨm as measured by the polarization-
responsive mitochondrial tracker CMXRos.
Moreover, as possible to seewith the immunoﬂuorescent staining of
COX5B, dopamine treatment caused the fragmentation of mitochondri-
al network and altered their architecture (Fig. 4B).Fig. 4. Effect of dopamine treatment on mitochondrial potential and network. Panel A
reports the staining of mitochondria with Mitotracker CMXRos and shows the loss of
the mitochondrial inner membrane potential ΔΨm after 24 h dopamine treatment. Open
bars: control; ﬁlled bars: 24 h dopamine treatment. **, p b 0.005. Panel B shows the effect
of dopamine treatment on the mitochondrial network, visualized by immunoﬂuorescent
staining of COX5B. Left: control (Ctr); right: 24 h dopamine treatment.3.6. Effect of autophagic and proteasomal degradation on VDACs
To investigate whether the decrease of VDAC1 and VDAC2 level may
be ascribed to the activation of autophagy, we evaluated the autophagic
activationmarker LC3-II after dopamine treatment in the absence and in
the presence of the lysosomal inhibitor chloroquine (Fig. 5A). Dopamine
induced autophagy, as demonstrated by the increase of LC3-II after 24 h
dopamine treatment. Additionally, LC3-II accumulated as a conse-
quence of the inhibition of lysosomal degradation by chloroquine both
in control and treated cells, thus indicating that under these conditions
the autophagic process is not impaired. As far as VDACs are concerned,
the reduction observed after dopamine treatment is not affected bychloroquine, thus suggesting that the dopamine-induced decrease is
not autophagy-mediated.
To evaluate thepossibility that VDACsmight be degraded by the pro-
teasome, cells exposed to dopamine toxic insult were treated with
Fig. 5.VDACs are not degraded by lysosomes nor byUPS after dopamine treatment. Panel A: First lane, control. Second lane, 24 h dopamine treatment. Third lane, control in the presence of
chloroquine. Fourth lane, 24 h dopamine treatment in the presence of chloroquine. Panel B: First lane, control. Second lane, control in the presence of MG132. Third lane, 24 h dopamine
treatment. Fourth lane, 24 h dopamine treatment in the presence of MG132.
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to counteract VDAC degradation.
Since dopamine induces at the same time autophagy and VDAC
level lowering, we wanted to verify the effect of autophagy indepen-
dently of dopamine on VDAC degradation. Therefore, we induced
autophagy by direct inhibition of mammalian target-of-rapamycin
(m-TOR) to evaluate the effect on VDAC1 and VDAC2 levels. As re-
ported in Fig. 6, rapamycin did not induce VDAC1 expression at the
transcriptional level, nor altered the level of the protein product.
Conversely, VDAC2 was markedly upregulated at both mRNA and
protein levels.Fig. 6. Regulation of VDAC1 and VDAC2 by rapamycin. VDAC2 levels are upregulated by rapamy
contrary, no effect is observed on VDAC1 (panel C and D). *, p b 0.05.4. Discussion
Impaired dopamine homeostasis affects at various levels mitochon-
drial functionality [7,21]. Several data demonstrate that VDACs actively
regulate several cellular processes converging on mitochondria [1,3]. In
this view, results shown in the present study indicate a direct effect of
dopamine on VDAC levels due to increased protein degradation and a
marked alteration ofmitochondrial polarization, calcium inﬂux and net-
work integrity.
The preliminary observation that a single VDAC2 spot in a 2-DE gel
disappeared in SH-SY5Y cells after 24 h dopamine treatment [10] wascin (1 μM, overnight) both at themRNA (panel A) and at the protein level (panel B). On the
1821T. Alberio et al. / Biochimica et Biophysica Acta 1842 (2014) 1816–1822conﬁrmed byWestern blotting, with a signiﬁcant reduction of the total
protein level even at early time points. Additionally, also VDAC1
displayed a reduced level after 24 h treatment, although the reduction
was moderate and reached statistical signiﬁcance only at longer times
with respect to VDAC2. The third isoform, VDAC3, was also reduced
after 24 h (data not shown); however, the low expression level of
VDAC3 in SH-SY5Y cells and in general in brain tissue prompted us to
focus on the two major isoforms. Furthermore, VDAC3 has been recog-
nized to be the most ancient VDAC isoform, thus playing an ancestral
role in the VDAC paralogous family [22].
The observed reduction in VDAC level is a speciﬁc response to
dopamine. Indeed, the induction of apoptosis by carbonyl cyanide
m-chlorophenylhydrazone (CCCP, 20 μM, 24 h) and 1-methyl-4-
phenylpyridinium (MPP+, 2.5 mM, 24 h) did not induce the same
effect (data not shown).
Several molecular mechanisms leading to the lowering of VDAC
levels have been investigated in the present work. First, we observed
that the effect of dopamine on VDACs is not at the transcriptional
level. Worthy of note, the expression of VDAC1 and VDAC2 measured
by quantitative RT-PCR did not justify protein levels. Indeed, VDAC2
mRNA appeared to be constant during dopamine treatment, and
VDAC1 even showed a slight mRNA increase at early time points, thus
suggesting a post-translational regulation.
Extensive VDAC reduction was a surprising ﬁnding, considering that
VDACs are thoroughly used asmitochondrial housekeepingmarkers. As
a consequence, the observed reduction should be associated to exten-
sive loss of mitochondria. However, the number of mitochondria did
not change, as indicated by another mitochondrial housekeeping mark-
er, i.e., COX5B. This supports the view that VDACs are speciﬁcally de-
graded as a consequence of dopamine toxicity.
Next, we focused on the potential VDAC degradation by lysosomes,
as the ﬁnal step of autophagy. Dopamine toxicity induced autophagy,
in agreement with previous studies [23]. The autophagic process was
not impaired, as demonstrated by further accumulation of LC3-II after
the inhibition of lysosome activity by chloroquine,which increases lyso-
somes pH so to inactivate acidic proteases. Furthermore, these results
showed that the disappearance of VDACs was not a consequence of
mitophagy. Actually, chloroquine treatment was not able to prevent
their degradation. Accordingly, we should also exclude the recently pro-
posedmechanism ofmitochondria derived vesicles that target the lyso-
some as well. As a matter of fact, vesicles budding from mitochondria
have been described as a degradation mechanism of VDAC after ROS
exposure [24]. Since dopamine induces at the same time autophagy
and degradation of VDACs, we wanted to verify the effect of autophagy
induction on VDAC levels, through directmTOR inhibition by rapamycin
and independently of dopamine. Rapamycin caused a signiﬁcant in-
crease of VDAC2 and, in this case, the protein level was controlled tran-
scriptionally. Conversely, no effect was observed for VDAC1, neither at
the transcriptional nor at the protein level. This demonstrates that
autophagy is not responsible for VDAC disposal.
Another possible mechanism for VDAC degradation might be the
ubiquitin–proteasome system (UPS). Therefore, we tested whether
UPS inhibition could reduce or block dopamine-induced VDAC down-
regulation. However, dopamine treatments in the absence or in the
presence of MG132, a proteasome inhibitor, both led to the lowering
of VDAC levels. In our recent paper [21], we demonstrated the accumu-
lation of proteolytic peptides belonging to VDAC2 within isolated mito-
chondria, thus suggesting that VDAC degradation may be mediated by
the activation of mitochondrial proteases such as the intermembrane
space protease HTRA2/OMI [25].
VDACs are key regulators of Ca2+ ﬂux to the mitochondria [2]. No-
ticeably, the reduction of the Ca2+ intake observed in mitochondria
after 24 h dopamine treatment goes together with reduced levels of
both VDAC1 and VDAC2 proteins. Dopamine also decreased the mito-
chondrial membrane potential ΔΨm. The drop in ΔΨm was relevant
and signiﬁcant after 24 h. The mitochondrial depolarization might beascribed to the opening of mitochondrial permeability transition pore
induced by dopamine [26]. Under these conditions, dysfunctional mito-
chondria should be eliminated by the activation of mitophagy [14,15].
Nevertheless, the number of mitochondria was not changed in the
present model of dopamine toxicity. Overall, present results seem to
suggest the permanence of depolarized mitochondria in these cells
and therefore the activation of toxic processes, i.e., ROS generation and
apoptosis [10]. VDAC1 has been already associated to the recognition
of dysfunctional mitochondria by the autophagosome [14], but it is
still not clear if its role is essential [15]. Even if its reduction cannot
completely justify the mitophagy impairment, it is probable that in
the present toxicity model the complex network of proteins involved
in the recognition of dysfunctional mitochondria and their degradation
is somehow altered. In agreement with the decrease in membrane po-
tential and inmitochondrial Ca2+ uptake, dopamine treatment strongly
affected the integrity of mitochondrial network. In conclusion, alter-
ation of dopamine homeostasis in an established cellular model [5] in-
duced a mitochondrial functional perturbation not counteracted by
the mitophagy quality control. As a consequence, the elimination of
VDACs might contribute to the altered mitochondrial disposal in PD
pathogenesis, thus enhancing the role of oxidative stress, and might
explain, at least partially, the selective cell death of dopaminergic neu-
rons in PD.
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